Demonstration series

RIQA Analytical Demonstration Studies

These studies illustrate how the RIQA framework evaluates analytical integrity across three primary domains. They demonstrate the verification methodology, finding classification system, and integrity scoring framework — not client outcomes.

Framework demonstration series. These studies utilize synthetic and reconstructed datasets derived from publicly available analytical patterns and are intended solely to illustrate the RIQA verification methodology and reporting framework. They are not client engagements, real studies, or validated deployments. Initial collaborative pilot engagements with research institution partners are currently in development.
RIQA-CS-BIO-001 Preclinical & Biomedical Research
Pre-Publication Assurance · Computational Vascular Biology
A research group engaged RIQA for pre-publication methodological assurance of a multi-modal vascular biology study integrating bulk RNA-seq, single-cell transcriptomics, in vivo phenotyping, and image-based lesion quantification.
F-301 · scRNA-seq cluster boundary instabilityModerate
F-302 · Cell-type specificity attenuationModerate
F-303 · Pathway FDR threshold sensitivityModerate
F-304 · SELE fold change sensitivityMinor
81/ 100Verified with notes
Biological direction preserved across all reconstruction workflows.
RIQA-CS-CLI-001 Clinical Research & Trial Analytics
Pre-NDA Assurance · Phase III Oncology Survival Analysis
A pharmaceutical sponsor engaged RIQA for pre-NDA independent external analytical assurance of a Phase III randomized trial in advanced NSCLC. Primary endpoint: progression-free survival.
F-101 · Censoring rule implementation gapModerate
F-102 · p-value sensitivity to censoringModerate
F-103 · SAP tie-handling underspecifiedMinor
82/ 100Verified with notes
Treatment direction preserved. Significance not maintained across 4 of 6 sensitivity scenarios.
RIQA-CS-CMS-001 Healthcare Analytics & Quality Assurance
Pre-Submission Verification · Medicare Advantage Risk Adjustment
A healthcare analytics team submitted a hierarchical logistic regression model for risk-adjusted readmission rate verification prior to CMS quality reporting across 142,800 beneficiaries and 14 providers.
F-201 · HCC look-back window mismatch (12 vs 24 mo)Major
F-202 · ICD-10 crosswalk version discrepancyModerate
F-203 · ETL transformation undocumentedMinor
72/ 100Methodological concerns
8.3% of beneficiaries affected. 3 of 14 providers crossed compliance threshold. Resubmission required.
About this series
Methodology over narrative
These demonstration studies were developed to show how the RIQA framework reasons through complex analytical integrity problems — not to simulate a client portfolio. The value is in the methodology: the finding classification logic, the verification vocabulary, the integrity scoring framework, and the structured quality assurance report format.
RIQA's first real pilot engagements are currently in development with collaborating research institution partners. If you are interested in participating in a pilot engagement, contact us through the form below.
Interested in a pilot engagement?
Real data. Real findings. No commitment required at this stage.